The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2486-2491

  Pedersen, Tanja X ^a,b   Binder, Christoph J ^c   Fredrikson, Gunilla N ^d   Nilsson, Jan ^d   Bro, Susanne ^a   Nielsen, Lars B ^a,b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atherosclerosis; oxLDL immunization; uraemia

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B PEPTIDE P45; APOLIPOPROTEIN E; BOVINE SERUM ALBUMIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; APOB PROTEIN, MOUSE; CYTOKINE; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; UREMIA; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PROCEDURES;

ANIMALS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNIZATION; IMMUNOGLOBULIN G; INFLAMMATION; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; UREMIA;

EID: 77954805100     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq059     Document Type: Article

References (28)

1. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 Study. Kidney Int 2003; 63: 1462-1467
2. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
3. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364-1372
4. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55 (Pubitemid 36044403)
5. Wanner C, Krane V, Marz Wet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
6. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
7. Himmelfarb J. Relevance of oxidative pathways in the pathophysiol- ogy of chronic kidney disease. Cardiol Clin 2005; 23: 319-330
8. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
9. Bro S, Bentzon JF, Falk E et al. Chronic renal failure accelerates ath- erogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14: 2466-2474
10. Bro S, Binder CJ, Witztum JL et al. Inhibition of the renin-angio- tensin system abolishes the proatherogenic effect of uremia in apo- lipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1080-1086
11. Bro S, Flyvbjerg A, Binder CJ et al. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 2008; 201: 274-280
12. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887
13. Mayr M, Kiechl S, Tsimikas S et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 2006; 47: 2436-2443
14. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-883
15. Bergesio F, Monzani G, Ciuti R et al. Autoantibodies against oxidized LDL in chronic renal failure: role of renal function, diet, and lipids. Nephron 2001; 87: 127-133
16. Fredrikson GN, Andersson L, Soderberg I et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 2005; 38: 171-179
17. Bro S, Moeller F, Andersen CB et al. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-defi- cient mice. J Am Soc Nephrol 2004; 15: 1495-1503
18. Binder CJ, Hartvigsen K, Chang MK et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437
19. Pedersen TX, Bro S, Andersen MH et al. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipopro- tein-E deficient mice. Atherosclerosis 2009; 202: 372-381
20. Davenport P, Tipping PG. The role of interleukin-4 and interleukin- 12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-1125
21. Mallat Z, Taleb S, it-Oufella H et al. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009; 50 Suppl: S364-369
22. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF- alpha: central factors in the altered cytokine network of uremia- the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
23. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432
24. Zhou X, Caligiuri G, Hamsten A et al. LDL immunization induces T- cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-114
25. Fredrikson GN, Bjorkbacka H, Soderberg I et al. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 trans- genic mice without inducing an increase in peptide-specific antibodies. J Intern Med 2008; 264: 563-570
26. Freigang S, Horkko S, Miller E et al. Immunization of LDL receptor- deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-1982
27. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 95-100
28. Chyu KY, Reyes OS, Zhao X et al. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (-/-) mice. Atherosclerosis 2004; 176: 27-35